The percentage of days with genital lesions was also significantly reduced , from @ % in the placebo group to @ % in both the group receiving @ mg of pritelivir daily ( relative risk , @ ; @ % CI , @ to @ ) and the group receiving @ mg weekly ( relative risk , @ ; @ % CI , @ to @ ) .